About
Immuno-oncology
Areas of Focus
Categories
Biologics & BiopharmaceuticalBiotech
Team (13)
Alan Sandler
Alan Sandler, M.D.
ALX Oncology
team_member
Allison Dillon
Allison Dillon, Ph.D.Chief Operations Officer
ALX Oncology
team_member
Barbara Klencke
Barbara Klencke, M.D.Interim Chief Medical Officer
ALX Oncology
team_memberexecutive
Charles M
Charles M. Baum, M.D., Ph.D.
ALX Oncology
team_member
Chris H
Chris H. Takimoto, M.D., Ph.D., FACP
ALX Oncology
team_member
Corey Goodman
Corey Goodman, Ph.D.Chairman and Cofounder
ALX Oncology
team_memberboard_chair
Clinical Trials (12)
View allTotal Trials
12
As Lead Sponsor
9
As Collaborator
3
Total Enrollment
1,158
By Phase
PHASE1: 5PHASE1/PHASE2: 2PHASE2: 4PHASE2/PHASE3: 1
By Status
ACTIVE_NOT_RECRUITING: 4RECRUITING: 3COMPLETED: 3TERMINATED: 2
Clinical Trials Pipeline12 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
Today
Hover over trial bars to see details
Recent Trials
NCT07085091Lead Sponsor
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
PHASE1Recruiting
170 participants
Started: Aug 18, 2025 · Completed: Dec 31, 2027
NCT07007559Lead Sponsor
ASPEN-09: A Study of Evorpacept in Combination With Anti-cancer Therapies in Advanced / Metastatic Malignancies
PHASE1/PHASE2Recruiting
80 participants
Started: Apr 28, 2025 · Completed: Dec 31, 2027
NCT05467670Collaborator
Safety and Efficacy of Anti-CD47, ALX148 in Combination with Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer
PHASE2Recruiting
31 participants
Started: Mar 30, 2023 · Completed: Dec 31, 2031
NCT05524545Lead Sponsor
A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)
PHASE1Completed
36 participants
Started: Nov 2, 2022 · Completed: Jun 27, 2025
NCT05167409Collaborator
A Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer
PHASE2Active, not recruiting
48 participants
Started: Jul 28, 2022 · Completed: Mar 1, 2026
Locations (1)
Headquarters
South SF, CA, United States
Map
Loading map...